_256_384.jpg)
Drug Approval | June 24, 2024
Cipla gets 6 observations from USFDA for Goa facility
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The Issue opened on June 18, 2024 and closed on June 21, 2024
The company will now explore a buyer for its manufacturing site and exit in due course
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Subscribe To Our Newsletter & Stay Updated
